We are harnessing the power of LAI formulations to create stable, scalable innovative medicines to address critical unmet medical needs in Africa and other low-resource regions across multiple therapeutic areas to develop life-changing treatments and improve global healthcare accessibility.
Therapeutic Area Focus
Pipeline
Centaro Biosciences advances a focused portfolio of therapeutics designed to deliver durable biological effect in diseases where sustained target modulation is required for meaningful clinical benefit.
Development Model
Centaro advances programs through defined stages:
Scientific and translational evaluation
Regulatory pathway assessment
Development planning and milestone definition
IND-enabling or early clinical advancement
Programmes progress only upon meeting predefined technical and regulatory criteria.
Current Activites
Centaro is actively evaluating therapeutic programs across selected indications. Program-specific disclosures will follow formal licensing agreements and appropriate development milestones.
Our programmes originate from validated human biology and progress through a structured translational framework linking mechanism, exposure, and response.
This approach produces well-characterised candidates suitable for regulatory engagement and partnership, while reducing uncertainty at clinical entry.